Your browser is no longer supported. Please, upgrade your browser.
Settings
EXEL Exelixis, Inc. daily Stock Chart
EXEL [NASD]
Exelixis, Inc.
Index- P/E- EPS (ttm)-0.30 Insider Own1.00% Shs Outstand290.87M Perf Week-5.08%
Market Cap6.08B Forward P/E41.49 EPS next Y0.50 Insider Trans-31.70% Shs Float273.43M Perf Month-3.82%
Income-70.20M PEG- EPS next Q-0.02 Inst Own82.80% Short Float7.47% Perf Quarter28.13%
Sales191.50M P/S31.76 EPS this Y63.70% Inst Trans8.67% Short Ratio3.87 Perf Half Y41.86%
Book/sh0.31 P/B67.45 EPS next Y888.24% ROA-13.30% Target Price25.00 Perf Year417.57%
Cash/sh1.44 P/C14.49 EPS next 5Y46.00% ROE127.20% 52W Range3.64 - 23.49 Perf YTD40.24%
Dividend- P/FCF29.73 EPS past 5Y-19.90% ROI-15.10% 52W High-10.98% Beta1.93
Dividend %- Quick Ratio1.70 Sales past 5Y-7.90% Gross Margin96.60% 52W Low474.45% ATR0.96
Employees287 Current Ratio1.70 Sales Q/Q683.80% Oper. Margin-21.90% RSI (14)47.23 Volatility4.44% 4.57%
OptionableYes Debt/Eq2.12 EPS Q/Q166.70% Profit Margin-36.70% Rel Volume0.63 Prev Close20.31
ShortableYes LT Debt/Eq0.00 EarningsFeb 27 AMC Payout- Avg Volume5.28M Price20.91
Recom2.00 SMA20-4.37% SMA500.87% SMA20046.08% Volume3,344,198 Change2.95%
Mar-16-17Initiated Oppenheimer Perform
Feb-28-17Downgrade Stifel Buy → Hold $21 → $22
Nov-03-16Initiated Deutsche Bank Buy $17
Oct-10-16Upgrade Piper Jaffray Neutral → Overweight
Sep-15-16Reiterated Stifel Buy $12 → $15
Aug-04-16Reiterated Stifel Buy $10 → $12
Jun-21-16Reiterated Leerink Partners Outperform $8 → $10
Apr-26-16Reiterated Stifel Buy $7 → $8
Apr-04-16Upgrade Stifel Hold → Buy $7
Jan-19-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-02-14Downgrade Stifel Buy → Hold
Feb-07-14Reiterated Stifel Buy $9 → $11
Jan-21-14Reiterated Maxim Group Buy $7.50 → $11
Nov-12-13Upgrade Maxim Group Hold → Buy $7.50
May-28-13Downgrade Maxim Group Buy → Hold $35 → $35
Nov-30-12Reiterated Stifel Nicolaus Buy $8 → $9
Apr-20-12Initiated Maxim Group Buy $9
Mar-15-12Resumed Stifel Nicolaus Buy $8
Aug-17-11Initiated Stifel Nicolaus Hold $8
Nov-18-09Downgrade Merriman Buy → Neutral
Mar-16-17 09:30AM  When Profit Makers Can Be Active Profit Takers Accesswire
07:36AM  Coverage initiated on Exelixis by Oppenheimer
Mar-15-17 08:21AM  Why Exelixis Is Already Up 55% This Year at Motley Fool
Mar-14-17 07:23AM  The 3 Most Important Numbers for Exelixis, Inc. at Motley Fool
Mar-13-17 10:11AM  Top Stocks That Are Already Crushing the Market in 2017 at Motley Fool
Mar-12-17 07:21AM  3 Horrible Stocks for Retirees at Motley Fool
Mar-07-17 05:42PM  Is Exelixis' Balance Sheet Safe? at Motley Fool
08:47AM  3 Factors That Drove Exelixis, Inc. Higher By 19% in February at Motley Fool
Mar-06-17 01:39PM  ETFs with exposure to Exelixis, Inc. : March 6, 2017
09:04AM  Exelixis' Cabozantinib Granted Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma Business Wire
Mar-04-17 07:25PM  Icahn's (Potential) Move Into Biotech
Mar-03-17 01:04PM  EXELIXIS, INC. Financials
08:15AM  Blog Coverage Intercept Pharmaceuticals Received NICE Approval for Ocaliva for Use in England, Wales and Northern Ireland Accesswire
Mar-02-17 11:47AM  Exelixis, Inc. :EXEL-US: Earnings Analysis: 2016 By the Numbers : March 2, 2017
09:30AM  Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis
Mar-01-17 04:05PM  Exelixis Announces Webcasts of Investor Conference Presentations in March Business Wire
03:19PM  M&As, Pipeline Catalysts to Drive Pharma Sector
10:40AM  Exelixis, Inc. Turns a Profit, but Don't Get Too Excited at Motley Fool
09:02AM  Exelixis, Inc. :EXEL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 1, 2017
07:24AM  Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals
Feb-28-17 06:15PM  Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire -6.76%
04:13PM  Kite, Ionis Outplay Med Sector As Perrigo, Tenet, Valeant Dive
11:46AM  Exelixis (EXEL) Reports Q4 Earnings, Revenues Beat Y/Y
10:50AM  Exelixis 4Q Net 12 Cents a Share Vs Loss Last Year at Investopedia
10:17AM  Exelixis In Cancer Deals With Roche, Bristol Myers at Investopedia
09:30AM  Zacks.com featured highlights: Exelixis, U.S. Silica Holdings, Intuit and RPC
02:42AM  Edited Transcript of EXEL earnings conference call or presentation 27-Feb-17 10:00pm GMT
Feb-27-17 05:18PM  Exelixis tops Street 4Q forecasts +6.45%
05:00PM  Exelixis Inc Earnings Call scheduled for 5:00 pm ET today
04:34PM  Exelixis Rockets On Bristol, Roche I-O Ties Following Merck-Incyte Team
04:11PM  EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
04:05PM  Exelixis Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update Business Wire
12:02PM  Exelixis shares jump after team up with Bristol-Myers on cancer trials at CNBC
08:56AM  Cooper (COO) to Report Q1 Earnings: Is a Surprise in Store?
07:07AM  Q4 2016 Exelixis Inc Earnings Release - After Market Close
07:01AM  Exelixis Announces Clinical Trial Collaboration with Roche to Evaluate Cabozantinib and Atezolizumab in Locally Advanced or Metastatic Solid Tumors Business Wire
06:59AM  Exelixis and Bristol-Myers Squibb Enter Clinical Collaboration for Late-Stage Combination Trial in First-Line Renal Cell Carcinoma Business Wire
06:44AM  4 Stocks to Buy with Superb Earnings Acceleration
Feb-24-17 05:06PM  Keryx (KERX) Q4 Earnings: What's in Store for the Stock?
08:38AM  Why Earnings Season Could Be Great for Exelixis (EXEL)
07:49AM  Tenet Healthcare (THC) Q4 Earnings: What's in the Cards?
Feb-23-17 04:43PM  Endocyte (ECYT) to Post Q4 Earnings: What's in the Cards?
04:23PM  Horizon (HZNP) Q4 Earnings: Stock Likely to Disappoint?
04:16PM  ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time?
09:45AM  TriMas (TRS) to Post Q4 Earnings: What's in the Cards?
Feb-22-17 03:10PM  Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?
08:16AM  Can Penumbra (PEN) Spring a Surprise this Earnings Season?
Feb-21-17 08:46AM  Patterson Companies (PDCO) Q3 Earnings: What's in Store?
Feb-20-17 07:52AM  Forget Alexion, Buy these 4 Biotech Stocks Instead
05:15AM  Medtronic (MDT) Q3 Earnings: Disappointment in the Cards?
Feb-17-17 05:02PM  Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors Business Wire
02:30PM  Radius Health (RDUS) Q4 Earnings: Will the Stock Disappoint?
09:30AM  Easier Regulatory Environment Could Send Biotech Industry Skyrocketing in 2017: Today's Reports on Neuralstem and Exelixis Accesswire
Feb-15-17 02:44PM  Two Great Stock Ideas in the IBB Biotech ETF at Investopedia
Feb-14-17 09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics
Feb-13-17 05:17PM  Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb at Motley Fool
09:14AM  Forget Gilead, Buy These 5 Biotech Stocks Instead
Feb-10-17 09:42AM  Can Allscripts (MDRX) Surprise Investors in Q4 Earnings?
09:30AM  Zacks.com featured highlights: Exelixis, RPC, Unit and Fortress Transportation and Infrastructure Investors
04:10AM  Exelixis (EXEL) Shares March Higher, Can It Continue?
Feb-09-17 12:37PM  Harry Boxers stocks to watch: biotechnology and technology at MarketWatch
10:15AM  Ecolab (ECL): What's in the Cards this Earnings Season?
09:27AM  Buy 4 Stocks Riding High on Superb Earnings Acceleration
07:39AM  5 Drug Stocks Poised to Beat Earnings Estimates in Q4
Feb-08-17 04:53PM  3 Scorching Hot Biotech Stocks -- Are They Buys? at Motley Fool +5.06%
01:49PM  Four Biotech Stocks Breaking Out at Forbes
10:10AM  DENTSPLY (XRAY) Q4 Earnings: Is Disappointment in Store?
09:30AM  The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma
09:30AM  The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals
Feb-07-17 04:05PM  Exelixis to Present at the Leerink Partners Global Healthcare Conference on February 15 Business Wire
03:26PM  5 Great Biotech Stocks to Buy Now
07:41AM  4 Drug Stocks that are Broker Favorites
Feb-03-17 11:17AM  Hopes for Tax Reform, Less Regulation Lift Indices +8.40%
Feb-02-17 04:05PM  Exelixis to Release Fourth Quarter and Full Year 2016 Financial Results on Monday, February 27, 2017 Business Wire
07:37AM  2 Big Reasons Exelixis, Inc. Soared 22% in January at Motley Fool
Feb-01-17 08:15AM  Blog Coverage Exelixis Partners with Takeda to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan Accesswire
Jan-31-17 04:05PM  Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
11:24AM  Exelixis, Takeda Sign Japanese Cancer Drug Deal at Investopedia
07:00AM  Exelixis Inks Partnership with Takeda for Cabometyx in Japan
Jan-30-17 06:00PM  Exelixis and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan Business Wire
07:27AM  3 Mid-Cap Biotech Stocks to Buy in February at Motley Fool
Jan-27-17 09:45AM  Biotech M&A Activity Expected to Rise in 2017: Latest Reports on Exelixis and Vertex Pharmaceuticals Accesswire
Jan-23-17 05:27PM  Better Buy: Exelixis, Inc. vs. Novartis at Motley Fool
Jan-11-17 10:49AM  Exelixis, Inc. Value Analysis (NASDAQ:EXEL) : January 11, 2017
Jan-10-17 12:21PM  After ARIAD's Acquisition, These 3 Cancer Drug Stocks Could Be Next at Motley Fool +7.57%
09:27AM  4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal
09:20AM  Genentech Withdraws Cost Claims Against Exelixis at Investopedia
07:23AM  Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : January 10, 2017
Jan-09-17 04:14PM  Why Exelixis, Inc. Stock Zoomed Higher Today at Motley Fool +14.75%
07:25AM  3 Stocks Expected to More Than Double Their Earnings in 2017 at Motley Fool
05:13AM  Update on Dispute between Exelixis and Genentech, a Member of the Roche Group Business Wire
Jan-05-17 09:43AM  The 4 Building Blocks That Pushed Exelixis, Inc. Higher by 164% in 2016 at Motley Fool
Jan-04-17 09:15AM  Biotech Stocks to Watch in 2017 ACADIA Pharmaceuticals and Exelixis Accesswire
08:49AM  How calls are looking for Exelixis rally
07:24AM  Is It Too Late to Buy Exelixis Stock? at Motley Fool
Jan-03-17 06:07PM  Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
02:04PM  ETFs with exposure to Exelixis, Inc. : January 3, 2017
10:08AM  Forget Gilead Sciences Inc.: These 2 Stocks Doubled Last Year at Motley Fool
Dec-30-16 04:22PM  Biotech Stocks: What to Watch in 2017 at Motley Fool
08:25AM  Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : December 30, 2016
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hessekiel JeffreyEVP and General CounselMar 22Option Exercise1.7055,00093,500301,617Mar 24 07:41 PM
Hessekiel JeffreyEVP and General CounselMar 22Sale20.5423,787488,585277,830Mar 24 07:41 PM
PAPADOPOULOS STELIOSDirectorMar 20Option Exercise10.5310,000105,3001,238,471Mar 21 07:28 PM
FELDBAUM CARL BDirectorMar 20Option Exercise10.5310,000105,30058,721Mar 21 07:29 PM
FELDBAUM CARL BDirectorMar 20Sale21.7710,000217,70048,721Mar 21 07:29 PM
PAPADOPOULOS STELIOSDirectorMar 20Sale21.6610,000216,6001,228,471Mar 21 07:28 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMar 15Option Exercise6.2050,007310,179208,060Mar 17 07:51 PM
WILLSEY LANCEDirectorMar 15Option Exercise10.5310,000105,300578,273Mar 17 07:52 PM
WILLSEY LANCEDirectorMar 15Sale22.8610,000228,600568,273Mar 17 07:52 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMar 15Sale22.5350,0071,126,658158,053Mar 17 07:51 PM
COHEN CHARLESDirectorMar 13Sale21.8210,000218,200238,180Mar 14 08:12 PM
MARCHESI VINCENT TDirectorMar 10Option Exercise3.1340,000125,200160,070Mar 10 07:37 PM
MARCHESI VINCENT TDirectorMar 10Sale21.9840,000879,200120,070Mar 10 07:37 PM
MORRISSEY MICHAELPresident and CEOMar 06Option Exercise9.91100,000991,000160,000Mar 07 07:56 PM
MORRISSEY MICHAELPresident and CEOMar 06Sale22.61100,0002,261,00060,000Mar 07 07:56 PM
MORRISSEY MICHAELPresident and CEOMar 03Option Exercise9.91100,000991,000160,000Mar 07 07:56 PM
Hessekiel JeffreyEVP and General CounselMar 03Option Exercise7.27100,000727,000346,617Mar 07 08:00 PM
Senner Christopher J.EVP and CFOMar 03Sale22.8011,000250,800100,398Mar 03 08:20 PM
Hessekiel JeffreyEVP and General CounselMar 03Sale23.04100,0002,303,678246,617Mar 07 08:00 PM
MORRISSEY MICHAELPresident and CEOMar 03Sale22.83100,0002,283,00060,000Mar 07 07:56 PM
Haley Patrick J.Sr. Vice President, CommercialMar 03Sale23.042,50057,600107,193Mar 07 07:45 PM
POSTE GEORGEDirectorMar 02Option Exercise4.5167,400303,660144,955Mar 03 08:17 PM
POSTE GEORGEDirectorMar 02Sale22.5867,4001,521,89277,555Mar 03 08:17 PM
POSTE GEORGEDirectorMar 01Option Exercise10.538,85093,19186,405Mar 03 08:17 PM
Lamb PeterEVP, Scientific Strategy & CSOMar 01Option Exercise7.3645,000331,350118,600Mar 03 08:18 PM
Lamb PeterEVP, Scientific Strategy & CSOMar 01Sale22.1945,000998,55073,600Mar 03 08:18 PM
POSTE GEORGEDirectorMar 01Sale22.188,850196,29377,555Mar 03 08:17 PM
Lamb PeterEVP, Scientific Strategy & CSOFeb 01Option Exercise6.9270,000484,300143,600Feb 03 07:55 PM
Lamb PeterEVP, Scientific Strategy & CSOFeb 01Sale18.6570,0001,305,50073,600Feb 03 07:55 PM
Lamb PeterEVP, Scientific Strategy & CSOJan 03Option Exercise5.7470,000401,800143,600Jan 05 08:25 PM
Lamb PeterEVP, Scientific Strategy & CSOJan 03Sale14.6570,0001,025,63673,600Jan 05 08:25 PM
FELDBAUM CARL BDirectorDec 16Option Exercise10.4125,000260,25073,721Dec 16 07:29 PM
FELDBAUM CARL BDirectorDec 16Sale17.0325,000425,75048,721Dec 16 07:29 PM
Garber Alan MDirectorDec 09Option Exercise10.5310,000105,30069,161Dec 09 08:02 PM
Garber Alan MDirectorDec 09Sale16.907,832132,36161,329Dec 09 08:02 PM
SCANGOS GEORGE ADirectorDec 07Option Exercise8.993563,2001,463,824Dec 07 07:03 PM
SCANGOS GEORGE ADirectorDec 07Sale17.901763,1501,463,648Dec 07 07:03 PM
SCANGOS GEORGE ADirectorDec 05Option Exercise8.99357,9763,218,2041,668,186Dec 07 07:03 PM
SCANGOS GEORGE ADirectorDec 05Sale17.81204,7183,646,0281,463,468Dec 07 07:03 PM
Schwab GiselaPres Prod Dev & Med Aff & CMODec 01Option Exercise8.9922,000197,780180,053Dec 02 07:13 PM
Lamb PeterEVP, Scientific Strategy & CSODec 01Option Exercise5.2770,000368,800143,600Dec 02 07:14 PM
Lamb PeterEVP, Scientific Strategy & CSODec 01Sale16.6670,0001,166,20073,600Dec 02 07:14 PM
Schwab GiselaPres Prod Dev & Med Aff & CMODec 01Sale16.7322,000368,060158,053Dec 02 07:13 PM
Lamb PeterEVP, Scientific Strategy & CSONov 09Option Exercise5.1770,000362,000143,600Nov 14 07:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMONov 09Option Exercise8.9922,000197,780180,053Nov 14 07:36 PM
MORRISSEY MICHAELPresident and CEONov 09Option Exercise8.99200,0001,798,000260,000Nov 14 07:37 PM
MORRISSEY MICHAELPresident and CEONov 09Sale15.00200,0003,000,00060,000Nov 14 07:37 PM
Schwab GiselaPres Prod Dev & Med Aff & CMONov 09Sale15.0022,000330,000158,053Nov 14 07:36 PM
Lamb PeterEVP, Scientific Strategy & CSONov 09Sale13.1570,000920,50073,600Nov 14 07:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 31Option Exercise9.73132,6621,290,801267,596Sep 02 04:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 31Sale10.98131,1551,440,082136,441Sep 02 04:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 04Option Exercise9.7342,338411,949174,354Aug 05 07:29 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 04Sale11.0042,338465,718132,016Aug 05 07:29 PM
Hessekiel JeffreyEVP and General CounselJun 01Option Exercise1.70200,000340,000230,367Jun 02 06:37 PM
WILLSEY LANCEDirectorMay 11Buy4.9520,00099,000568,273May 11 05:23 PM
WILLSEY LANCEDirectorMay 09Buy4.9740,000198,900548,273May 11 05:23 PM